[go: up one dir, main page]

PT3943070T - Long-acting formulations of bedaquiline - Google Patents

Long-acting formulations of bedaquiline

Info

Publication number
PT3943070T
PT3943070T PT211785266T PT21178526T PT3943070T PT 3943070 T PT3943070 T PT 3943070T PT 211785266 T PT211785266 T PT 211785266T PT 21178526 T PT21178526 T PT 21178526T PT 3943070 T PT3943070 T PT 3943070T
Authority
PT
Portugal
Prior art keywords
bedaquiline
long
acting formulations
formulations
acting
Prior art date
Application number
PT211785266T
Other languages
Portuguese (pt)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3943070T publication Critical patent/PT3943070T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
PT211785266T 2018-04-16 2018-07-13 Long-acting formulations of bedaquiline PT3943070T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18167463 2018-04-16

Publications (1)

Publication Number Publication Date
PT3943070T true PT3943070T (en) 2024-02-06

Family

ID=62002070

Family Applications (2)

Application Number Title Priority Date Filing Date
PT187398565T PT3651736T (en) 2018-04-16 2018-07-13 Long-acting formulations
PT211785266T PT3943070T (en) 2018-04-16 2018-07-13 Long-acting formulations of bedaquiline

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT187398565T PT3651736T (en) 2018-04-16 2018-07-13 Long-acting formulations

Country Status (2)

Country Link
EA (1) EA202090287A1 (en)
PT (2) PT3651736T (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355606A1 (en) * 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations

Also Published As

Publication number Publication date
PT3651736T (en) 2021-09-24
EA202090287A1 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
HUE064651T2 (en) Long-acting formulations of bedaquiline
PL3474822T3 (en) Formulations of brincidofovir
GB201809976D0 (en) Novel formulations
IL272857A (en) Formulations of copanlisib
GB201707189D0 (en) Novel formulations
IL280906A (en) Formulations of ag10
ZA201905379B (en) 1-amino-1-cyclopropanecaboxylic acid formulations
GB201905477D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
IL284691A (en) Formulations
IL283593A (en) Oral formulations of branaplam
GB201707187D0 (en) Novel formulations
PT3678644T (en) Formulations of copanlisib
PT3943070T (en) Long-acting formulations of bedaquiline
HK40120600A (en) Formulations of brincidofovir
HK40115807A (en) Formulations of brincidofovir
HK40105712A (en) Formulations of brincidofovir
SG11202011823SA (en) Activator-nucleator formulations
GB201911063D0 (en) Formulations
GB201819028D0 (en) Butanol-based formulations
GB201905105D0 (en) Formulations
GB201808386D0 (en) Formulations
GB201804545D0 (en) Formulations
GB201803201D0 (en) Formulations
GB201716291D0 (en) Novel formulations